Third party
-
Convene, 133 Houndsditch, London, EC3A 7BX
BioTrinity 2026, the 20th edition of OBN's flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend.
Who attends?
BioTrinity is attended by an ever-evolving international audience of c.850 delegates, comprising a mix of academic entrepreneurs, early stage and emerging life sciences R&D companies, funders & investors, big pharma teams, charities & research bodies, government, regulatory bodies, along with professional services and expert supporters to the industry.
What's new for 2026?
- A showcase of 100 research updates ranging from Academic Posters to Pre-Seed, Seed, Series A & B stage R&D companies
- A dedicated one-day session showcasing opportunities for growth in international markets
- A new and much demanded 'mentor match-making lunch' for early stage Founders & CEOs to meet with those that can provide support and guidance.
- An increased Big Pharma presence
- A focus on unlocking access to alternative sources of funding